Health on MSN

What happens if you forget an antibiotic dose

Skipping antibiotic doses can lower drug levels and reduce effectiveness. • Missing doses—especially multiple—can slow ...
The American Journal of Managed Care

Teclistamab Approved for Biweekly Dosing in R/R Multiple Myeloma

The bispecific antibody is used to treat patients with relapsed or refractory multiple myeloma (R/R MM) who have achieved and maintained a complete response for at least 6 months; this approval allows ...
Nasdaq

Regulus Therapeutics Completes Dosing in Phase 1 Multiple Ascending Dose Study of RGLS4326 in Healthy Volunteers for the Treatment of Autosomal Dominant Polycystic Kidney ...

LA JOLLA, Calif., July 22, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...
Monthly Prescribing Reference

Bevacizumab Safe, Stable for Multiple Dosing From Single Vial

(HealthDay News) — Bevacizumab is safe and stable when stored at 4 degrees Celsius, even with multiple dosing from a single vial, according to a study published in the July issue of Clinical & ...
News Medical

Extending dosing intervals makes common multiple sclerosis drug safer to use

A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS ...
Seeking Alpha

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...
Monthly Prescribing Reference

Biweekly Dosing Approved for Tecvayli in Relapsed/Refractory Multiple Myeloma

The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...
Business Insider

Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023

SAN DIEGO, March 3, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and ...
MarketWatch

Inmagene Announces Positive Topline Results of a Multiple Ascending Dose (MAD) Study of IMG-004, a Non-covalent Reversible BTK Inhibitor with Once Daily Dosing Potential

The MarketWatch News Department was not involved in the creation of this content. Inmagene Announces Positive Topline Results of a Multiple Ascending Dose (MAD) Study of IMG-004, a Non-covalent ...
Cure Today

Multiple Myeloma Progression Still Slowed With Reduced Tecvayli Dosing

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli. A reduced dosing schedule of Tecvayli (teclistamab) continued to slow the progression of ...
Nasdaq

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...